The molecular biology and therapeutic potential of Nrf2 in leukemia

por Khodakarami, Atefeh, Adibfar, Sara, Karpisheh, Vahid, Abolhasani, Shiva, Jalali, Pooya, Mohammadi, Hamed, Gholizadeh Navashenaq, Jamshid, Hojjat-Farsangi, Mohammad, Jadidi-Niaragh, Farhad
Publicado 2022

Targeted Silencing of NRF2 by rituximab-conjugated nanoparticles increases the sensitivity of chronic lymphoblastic leukemia cells to Cyclophosphamide

por Khodakarami, Atefeh, Kashani, Mahsa Afsari, Nazer, Atefeh, Kheshti, Armin Mahmoudsalehi, Rashidi, Bentolhoda, Karpisheh, Vahid, Masjedi, Ali, Abolhasani, Shiva, Izadi, Sepideh, Bagherifar, Rafieh, Hejazian, Seyyed Sina, Mohammadi, Hamed, Movassaghpour, AliAkbar, Feizi, Abbas Ali Hosseinpour, Hojjat-Farsangi, Mohammad, Jadidi-Niaragh, Farhad
Publicado 2023